Cantor Fitzgerald Reiterates Overweight on Jasper Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Jasper Therapeutics (NASDAQ:JSPR).
September 09, 2024 | 5:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald's analyst Josh Schimmer has reiterated an Overweight rating on Jasper Therapeutics, indicating a positive outlook on the stock.
The reiteration of an Overweight rating by a reputable analyst suggests confidence in Jasper Therapeutics' potential, likely leading to positive investor sentiment and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100